Skip to content

THAMEUS

Active
Public limited companyfounded 20242 years activeAvenue de l'Hôpital 11, 4000 Liège, BelgiumKBO/BCE: BE 1008.238.883
Summary

The annual accounts of THAMEUS for fiscal year 2025 show a net loss of 57% of the equity at the start of that year. The 2025 annual accounts show equity of €419,327 and a net result of -€120,416. Its solvency ranks better than 89% of 58 sector peers (NACE 21, fiscal year 2025). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21209
1 site
Size
€502,659total assets 2025
Equity
€419,327
Loss
-€120,416
Turnover not published (abridged schema)
Financial health
57 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Largest shareholder
NOSHAQ VENTURE · 29.39%
  • BMRF ConsultDirector · permanent representative François Boemer
Accounts 8 days early1 of 3 deeds read
Why 57Capped at 59: a net loss of at least half of total assets or of the equity at the start of the financial year- Loss of €120,416, the second in a row (FY 2025)+ Liquidity: current ratio 6.03, cash €451,599+ Size: total assets €502,659+ Sector Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)Show the evidence

Checked score

Score 2025
57 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 70% of its sector peers (NACE 21, micro)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that weighs is under Signals.
Financial strength · tick = 2024
Strong
Solvency 100=
equity 83.4% of total assets
Liquidity 96-2
short-term debt 16.6% · cash 89.8%
Profitability 0=
return on assets -24.0%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (154 companies)
Last 24 months 05-2025: 1.1% 06-2025: 1.1%● unchanged vs 05-2025highest value 07-2025: 0.1%▼ -1.0 percentage point vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026lowest value
Credit up to €23,000 at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 6.03 against 7.54 in 2024; short-term debt: 16.6% and cash: 89.8% of total assets), and 16.6% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro): better than 90% on solvency, 88% on liquidity, 13% on profitability and 91% on growth.

The bankruptcy probability was computed on 07-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals.
−lowers risk+raises risk○neutral
lowers risk · Liquidity: current ratio 6.03, cash €451,599
NBB · annual accounts
raises risk · Loss of €120,416, the second in a row (FY 2025)
NBB · annual accounts
lowers risk · Size: total assets €502,659
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
lowers risk · Sector Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
KBO
raises risk · Young company
Founded in 2024, under 3 years in business. Failure risk is statistically highest between 2 and 8 years after founding.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 y
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-07-2026, 8 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
8 days early
2024
37 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 2 accounts on average 23 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
07-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Checked from 2021 on.
KBO publications · our coverage
  1. Appointment: BMRF Consult (director)Permanent representative: François Boemer
  2. Annual accounts filedfiscal year 2025 · abbreviated…
  3. Annual accounts filedfiscal year 2024 · micro…

Key points

  • Positive: Equity rose in 2025from €209,743 to €419,327 ▲ 99.9% View
  • Positive: Among the best 11% on solvencysector median 45.7% · 58 companies 83.4% View
  • New directorlatest change 01-04-2026 · 1 in office 1 joined View

By topic

Financials

Fiscal year
2025
Total assets
€502,659
Loss
-€120,416
Solvency
83.4%
Total assets▲ 108%
Net result
20242025
Go to Financials

Board & ownership

Board
1 member
Largest shareholder
NOSHAQ VENTURE · 29.39%
  • BMRF ConsultDirector
Go to Board & ownership

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21209
Founded
10-04-2024
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.